Maria Fernanda Badue Pereira

Maria Fernanda Badue Pereira

Auto-generated profile, based on publicly available information

Maria Fernanda Badue Pereira

Universidade de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Clinics
Verified
Journal Article
Open access
MPMaria Fernanda Badue Pereira
Maria Fernanda Badue Pereira
NLNadia Litvinov
Nadia Litvinov
SFSylvia Costa Lima Farhat
Sylvia Costa Lima Farhat
AEAdriana Pasmanik Eisencraft
Adriana Pasmanik Eisencraft
MGMaria Augusta Bento Cicaroni Gibelli
Maria Augusta Bento Cicaroni Gibelli
PJPatricia Palmeira Daenekas Jorge
Patricia Palmeira Daenekas Jorge
To assess the outcomes of pediatric patients with laboratory-confirmed coronavirus disease (COVID-19) with or without multisystem inflammatory syndrome in children (MIS-C).This cross-sectional study included 471 samples collected from 371 patients (age<18 ...

17 November 2021 in Clinics
Verified
Journal Article
Open access
TFThais T. Fink
Thais T. Fink
HMHeloisa H.S. Marques
Heloisa H.S. Marques
BGBruno Gualano
Bruno Gualano
LLLivia Lindoso
Livia Lindoso
VBVera Bain
Vera Bain
YZYingying Zheng
Yingying Zheng
To prospectively evaluate demographic, anthropometric and health-related quality of life (HRQoL) in pediatric patients with laboratory-confirmed coronavirus disease 2019 (COVID-19) This was a longitudinal observational study of surviving pediatric post-COVID-19 patients (n=53) and pediatric subjects without laboratory-confirmed COVID-19 included as controls (n=52) was performed. The median duration between COVID-19 diagnosis (n=53) and follow-up was 4.4 months (0.8-10.7). Twenty-three of 53 (43%) patients reported at least one persistent symptom at the longitudinal follow-up visit and 12/53 (23%) had long COVID-19, with at least one symptom lasting for >12 weeks. The most frequently reported symptoms at the longitudinal follow-up visit were headache (19%), severe recurrent headache (9%), tiredness (9%), dyspnea (8%), and concentration difficulty (4%). At the longitudinal follow-up visit, the frequencies of anemia (11% versus 0%, p=0.030), lymphopenia (42% versus 18%, p=0.020), C-reactive protein level of >30 mg/L (35% versus 0%, p=0.0001), and D-dimer level of >1000 ng/mL (43% versus 6%, p=0.0004) significantly reduced compared with baseline values. Chest X-ray abnormalities (11% versus 2%, p=0.178) and cardiac alterations on echocardiogram (33% versus 22%, p=0.462) were similar at both visits. Comparison of characteristic data between patients with COVID-19 at the longitudinal follow-up visit and controls showed similar age (p=0.962), proportion of male sex (p=0.907), ethnicity (p=0.566), family minimum monthly wage (p=0.664), body mass index (p=0.601), and pediatric pre-existing chronic conditions (p=1.000). The Pediatric Quality of Live Inventory 4.0 scores, median physical score (69 [0-100] versus 81 [34-100], p=0.012), and school score (60 [15-100] versus 70 [15-95], p=0.028) were significantly lower in pediatric patients with COVID-19 at the longitudinal follow-up visit than in controls. Pediatric patients with COVID-19 showed a longitudinal impact on HRQoL parameters, particularly in physical/school domains, reinforcing the need for a prospective multidisciplinary approach for these patients. These data highlight the importance of closer monitoring of children and adolescents by the clinical team after COVID-19.

17 November 2021 in Clinics
Verified
Journal Article
Open access
HMHeloisa Helena de Sousa Marques
Heloisa Helena de Sousa Marques
MPMaria Fernanda Badue Pereira
Maria Fernanda Badue Pereira
ASAngelica Carreira dos Santos
Angelica Carreira dos Santos
TFThais Toledo Fink
Thais Toledo Fink
CPCamila Sanson Yoshino de Paula
Camila Sanson Yoshino de Paula
HGHC-FMUSP Pediatric COVID Study Group
HC-FMUSP Pediatric COVID Study Group
To compare demographic/clinical/laboratory/treatments and outcomes among children and adolescents with laboratory-confirmed coronavirus disease 2019 (COVID-19). This was a cross-sectional study that included patients diagnosed with pediatric COVID-19 (aged <18 years) between April 11, 2020 and April 22, 2021. During this period, 102/5,951 (1.7%) of all admissions occurred in neonates, children, and adolescents. Furthermore, 3,962 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection samples were processed in patients aged <18 years, and laboratory-confirmed COVID-19 occurred in 155 (4%) inpatients and outpatients. Six/155 pediatric patients were excluded from the study. Therefore, the final group included 149 children and adolescents (n=97 inpatients and 52 outpatients) with positive SARS-CoV-2 results. The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p<0.05). Likewise, the frequencies of enoxaparin use (p=0.037), current immunosuppressant use (p=0.008), vasoactive agents (p=0.045), arterial hypotension (p<0.001), and shock (p=0.024) were significantly lower in children than in adolescents. Logistic regression analysis showed that adolescents with laboratory-confirmed COVID-19 had increased odds ratios (ORs) for sore throat (OR 13.054; 95% confidence interval [CI] 2.750-61.977; p=0.001), nausea (OR 8.875; 95% CI 1.660-47.446; p=0.011), and lymphopenia (OR 3.575; 95% CI 1.355-9.430; p=0.010), but also had less hospitalizations (OR 0.355; 95% CI 0.138-0.916; p=0.032). The additional logistic regression analysis on patients with preexisting chronic conditions (n=108) showed that death as an outcome was significantly associated with pediatric severe acute respiratory syndrome (SARS) (OR 22.300; 95% CI 2.341-212.421; p=0.007) and multisystem inflammatory syndrome in children (MIS-C) (OR 11.261; 95% CI 1.189-106. 581; p=0.035). Half of the laboratory-confirmed COVID-19 cases occurred in adolescents. Individuals belonging to this age group had an acute systemic involvement of SARS-CoV-2 infection. Pediatric SARS and MIS-C were the most important factors associated with the mortality rate in pediatric chronic conditions with COVID-19.

1 July 2021 in Journal of Infection
Verified
Journal Article
Closed access
CPCamila Sanson Yoshino de Paula
Camila Sanson Yoshino de Paula
GPGiovanna Gavros Palandri
Giovanna Gavros Palandri
TFTaiane Siraisi Fonseca
Taiane Siraisi Fonseca
TVThaís Cristina Annibale Vendramini
Thaís Cristina Annibale Vendramini
SFSylvia Costa Lima Farhat
Sylvia Costa Lima Farhat
PJPatricia Palmeira Daenekas Jorge
Patricia Palmeira Daenekas Jorge

1 January 2022 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
MPMaria Fernanda Bádue Pereira
Maria Fernanda Bádue Pereira
PSPriscila Suguita
Priscila Suguita
NLNadia Litvinov
Nadia Litvinov
SFSylvia Costa Lima Farhat
Sylvia Costa Lima Farhat
CPCamila Sanson Yoshino de Paula
Camila Sanson Yoshino de Paula
HMHeloisa Helena de Sousa Marques
Heloisa Helena de Sousa Marques
This study aims to assess COVID-19 and other respiratory viruses in pediatric patients. Between April 17 and September 30, 2020, we collected 1,566 respiratory samples from 1,044 symptomatic patients who were younger than 18 years old to assess SARS-CoV-2 infection. Of these, 919 were analyzed for other respiratory pathogens (ORP). Patients with laboratory-confirmed COVID-19 or ORP were included. We evaluated 76 pediatric COVID-19 infections and 157 other respiratory virus infections. Rhinovirus occurred in 132/157 (84%). COVID-19 patients who were significantly older, had more fevers, headaches and pneumonia than those with ORP. The median white blood cell count was lower in patients with SARS-CoV-2 than in those with ORP (6,470 versus 8,170; p=0.02). COVID-19 patients had significantly worse symptoms than those with ORP.

16 May 2023 in Children
Verified
Journal Article
Open access
PDF file
CACamilla Astley
Camilla Astley
GLGabriela Nunes Leal
Gabriela Nunes Leal
SGSaulo Gil
Saulo Gil
PSPriscila Suguita
Priscila Suguita
TFThais Fink
Thais Fink
BGBruno Gualano
Bruno Gualano
Objective: To assess the potential therapeutic role of exercise on health-related quality of life, assessed by the Pediatric Outcomes Data Collection Instrument (PODCI), coronary flow reserve (CFR), cardiac function, cardiorespiratory fitness, and inflammatory and cardiac blood markers in multisystemic inflammatory syndrome in children (MIS-C) patients. Methods: This is a case series study of a 12-wk, home-based exercise intervention in children and adolescents after MIS-C diagnosis. From 16 MIS-C patients followed at our clinic, 6 were included (age: 7–16 years; 3 females). Three of them withdrew before the intervention and served as controls. The primary outcome was health-related quality of life, assessed PODCI. Secondary outcomes were CFR assessed by 13N-ammonia PET-CT imaging, cardiac function by echocardiography, cardiorespiratory fitness, and inflammatory and cardiac blood markers. Results: In general, patients showed poor health-related quality of life, which seemed to be improved with exercise. Additionally, exercised patients showed improvements in coronary flow reserve, cardiac function, and aerobic conditioning. Non-exercised patients exhibited a slower pattern of recovery, particularly in relation to health-related quality of life and aerobic conditioning. Conclusions: Our results suggest that exercise may play a therapeutic role in the treatment of post-discharge MIS-C patients. As our design does not allow inferring causality, randomized controlled trials are necessary to confirm these preliminary findings.